文献速递消化道出血消化内镜

结肠息肉切除术后30天内出血的管理与结局:大型真实世界多中心队列研究

Management and Outcomes of Bleeding Within 30 Days of Colonic Polypectomy in a Large, Real-Life, Multicenter Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-04-06

该回顾性多中心队列纳入西班牙6家三级中心548例结肠息肉切除术后30天内出血患者,其中71.9%接受结肠镜检查、2.6%接受首选血管栓塞、25.5%未干预。研究发现近半数患者不需止血治疗,结肠镜常被过度使用;使用抗血栓药、血红蛋白下降>2 g/dL、血流动力学不稳定及合并症与需治疗干预独立相关。

要点

  • 近43%的息肉切除术后迟发出血患者无需任何止血治疗,结肠镜存在过度使用。
  • 抗血栓药使用、血红蛋白下降>2 g/dL、血流动力学不稳定及合并症提示需治疗干预。
  • 抗凝药、左侧息肉、既往电凝及带蒂形态增加结肠镜下活动性出血风险。

核心结论

  • 结肠息肉切除术后30天内出血患者中近半数不需治疗干预,结肠镜常被过度使用。
  • 活动性出血的独立危险因素包括抗凝药使用、左侧息肉、既往电凝和带蒂息肉形态。

研究设计与样本

  • 西班牙6家三级中心的回顾性研究,纳入2010年1月至2018年9月548例结肠息肉切除术后30天内出血患者。
  • 71.9%接受结肠镜检查,2.6%接受首选血管栓塞,25.5%未接受干预。

主要发现

  • 需治疗干预独立相关因素:使用抗血栓药、血红蛋白下降>2 g/dL、血流动力学不稳定及合并症(P < .05)。
  • 结肠镜下出血点识别于344例,其中74例(21.5%)存在活动性出血。
  • 活动性出血风险增加因素:抗凝药使用(OR 2.6;95% CI 1.5-4.5)、左侧息肉(OR 1.95;95% CI 1-3.8)、既往电凝(OR 2.6;95% CI 1.1-6.1)、带蒂息肉形态(OR 1.8;95% CI 1-3.2)。
  • 整体队列中43%无需任何止血治疗;未干预者再出血(<6%)和输血需求低。

关键数值与推荐

  • 活动性出血预测因素:抗凝药使用OR 2.6(95% CI 1.5-4.5)、左侧息肉OR 1.95(95% CI 1-3.8)、既往电凝OR 2.6(95% CI 1.1-6.1)、带蒂息肉OR 1.8(95% CI 1-3.2)。
  • 研究开发了可视化列线图评估活动性出血风险。

临床怎么用

  • 对结肠息肉切除术后30天内出血患者,应结合抗血栓药使用、血红蛋白下降、血流动力学及合并症评估是否需要干预。
  • 抗凝药使用、左侧息肉、既往电凝或带蒂息肉患者结肠镜下活动性出血风险较高,可优先考虑结肠镜。
  • 近半数患者可能无需止血治疗,应避免不必要的结肠镜检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Management of delayed (within 30 days) postpolypectomy bleeding (DPPB) has not been standardized. Patients often undergo colonoscopies that do not provide any benefit. We aimed to identify factors associated with therapeutic intervention and active bleeding after DPPB. METHODS: We performed a retrospective study of 548 patients with bleeding within 30 days after an index polypectomy (DPPB; 71.9% underwent colonoscopy, 2.6% underwent primary angiographic embolization, and 25.5% were managed without intervention) at 6 tertiary centers in Spain, from January 2010 through September 2018. We collected demographic and medical data from patients. The primary outcomes were the need for therapeutic intervention and the presence of active bleeding during colonoscopy. RESULTS: A need for therapeutic intervention was associated independently with the use of antithrombotic agents, hemoglobin decrease greater than 2 g/dL, hemodynamic instability, and comorbidities (P < .05). The bleeding point during colonoscopy was identified in 344 patients; 74 of these patients (21.5%) had active bleeding. Active use of anticoagulants (odds ratio [OR], 2.6; 95% CI, 1.5-4.5), left-sided polyps (OR, 1.95; 95% CI, 1-3.8), prior use of electrocautery (OR, 2.6; 95% CI, 1.1-6.1), and pedunculated polyp morphology (OR, 1.8, 95% CI, 1-3.2) significantly increased the risk of encountering active bleeding. We developed a visual nomogram to estimate the risk of active bleeding. Overall, 43% of the cohort did not require any hemostatic therapy. Rebleeding (<6%) and transfusion requirements were low in those managed without intervention. CONCLUSIONS: In a study of patients with DPPB, we found that almost half do not warrant any therapeutic intervention. Colonoscopy often is overused for patients with DPPB. We identified independent risk factors for active bleeding that might be used to identify patients most likely to benefit from colonoscopy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rodríguez de Santiago E, Hernández-Tejero M, Rivero-Sánchez L, et al. Management and Outcomes of Bleeding Within 30 Days of Colonic Polypectomy in a Large, Real-Life, Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2020. PMID: 32272252. doi:10.1016/j.cgh.2020.03.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。